Terns Pharmaceuticals Inc
NASDAQ:TERN

Watchlist Manager
Terns Pharmaceuticals Inc Logo
Terns Pharmaceuticals Inc
NASDAQ:TERN
Watchlist
Price: 40.11 USD -0.72% Market Closed
Market Cap: 3.6B USD

Terns Pharmaceuticals Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Terns Pharmaceuticals Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Terns Pharmaceuticals Inc
NASDAQ:TERN
Free Cash Flow
-$70.1m
CAGR 3-Years
-18%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Free Cash Flow
$19.6B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Free Cash Flow
$15.3B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
31%
Pfizer Inc
NYSE:PFE
Free Cash Flow
$10.4B
CAGR 3-Years
-24%
CAGR 5-Years
0%
CAGR 10-Years
-3%
Merck & Co Inc
NYSE:MRK
Free Cash Flow
$13B
CAGR 3-Years
-5%
CAGR 5-Years
14%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Free Cash Flow
$6.4B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
14%
No Stocks Found

Terns Pharmaceuticals Inc
Glance View

Market Cap
3.5B USD
Industry
Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The company is headquartered in Foster City, California and currently employs 41 full-time employees. The company went IPO on 2021-02-05. The firm is focused on developing a portfolio of small-molecule single-agent and combination therapy candidates to address diseases, such as non-alcoholic steatohepatitis (NASH) and obesity. Its lead program, TERN-101, is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR), agonist that has demonstrated a differentiated tolerability profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-501 is a thyroid hormone receptor beta (THR-B) agonist with metabolic stability and improved liver distribution. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. Its TERN-601 is its small-molecule Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist program that is intended to be orally administered for NASH and obesity.

TERN Intrinsic Value
Not Available

See Also

What is Terns Pharmaceuticals Inc's Free Cash Flow?
Free Cash Flow
-70.1m USD

Based on the financial report for Dec 31, 2024, Terns Pharmaceuticals Inc's Free Cash Flow amounts to -70.1m USD.

What is Terns Pharmaceuticals Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-1%

Over the last year, the Free Cash Flow growth was -4%. The average annual Free Cash Flow growth rates for Terns Pharmaceuticals Inc have been -18% over the past three years , -1% over the past five years .

Back to Top